A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) is a phase 2, interventional study registered as NCT06822543 by Latin American Cooperative Oncology Group, with a registry enrolment figure of 46 participants, started 2025-09-12 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pembrolizumab; Datopotamab deruxtecan; Carboplatin. Conditions listed: Lung Cancer; Non Small Cell Lung Cancer; Brain Metastases. Primary outcome: Confirmed Intracranial Objective Response Rate (iORR) as Measured by the RANO-BM Criteria. Lung eligibility wording from the registry: "\- Male/female participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of NSCLC will be enrolled in this study". Sites: Brazil. No results are recorded here; the registry entry is the source.